LP
VINC

LMR Partners’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

LMR Partners’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$8.1K – 1600
2024
Q2 		$8.1K Hold
500
– – ﹤0.01% 1018
2024
Q1 		$50.6K Hold
500
– – ﹤0.01% 985
2023
Q4 		$11.8K Hold
500
– – ﹤0.01% 854
2023
Q3 		$10.1K Sell
500
-2,445
-83% -$47.4K ﹤0.01% 820
2023
Q2 		$76.6K Sell
2,945
-55
-2% -$1.57K ﹤0.01% 636
2023
Q1 		$62.4K Hold
3,000
– – ﹤0.01% 966
2022
Q4 		$61.2K Sell
3,000
-147
-5% -$2.77K ﹤0.01% 1056
2022
Q3 		$87K Hold
3,147
– – ﹤0.01% 1063
2022
Q2 		$83K Buy
3,147
+587
+23% +$26.1K ﹤0.01% 1113
2022
Q1 		$205K Buy
+2,560
New +$316K ﹤0.01% 1141

Other funds holding VINC

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's VINC Position: Q3 2024 in Review

LMR Partners sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2024, closing a stake of 500 shares — an estimated $8.1K sold.

LMR Partners first reported a position in VINC in Q1 2022 and held it in 10 quarters. The position peaked at $205K in Q1 2022. 28 funds tracked by Wall St. Rank hold VINC as of Q3 2024.

  • LMR Partners reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • LMR Partners sold 500 Vincerx Pharma, Inc. Common Stock shares in Q3 2024, an estimated $8.1K.
  • LMR Partners first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • LMR Partners's Vincerx Pharma, Inc. Common Stock position peaked at $205K in Q1 2022.
  • 28 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.